T2 Biosystems develops and sells diagnostic products for detecting pathogens, biomarkers, and abnormalities in various patient sample types. The company offers several diagnostic panels, including T2Candida, T2Bacteria, T2Resistance, and T2Biothreat. These tests detect blood stream infections, sepsis, candidemia, and biothreat pathogens. The company is also developing T2Cauris and T2Lyme panels for detecting Candida auris and Lyme disease bacteria, respectively. Headquartered in Massachusetts, the company was incorporated in 2006.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 100.0 |